Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge L Juncos

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|October 20, 2012
Olfactory dysfunction in fragile X tremor ataxia syndromeJorge L Juncos, Joash T Lazarus, Julia Rohr, et al.
Archives of Neurology|November 16, 2002
Beneficial effects of testosterone replacement for the nonmotor symptoms of Parkinson diseaseMichael S Okun, Benjamin L Walter, William M McDonald, et al.
The Lancet. Neurology|November 14, 2009
Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disordersValerie Voon, Pierre-Olivier Fernagut, Jeff Wickens, et al.
Neurogenetics|February 1, 2011
New clinical findings in the fragile X-associated tremor ataxia syndrome (FXTAS)Jorge L Juncos, Joash T Lazarus, Emily Graves-Allen, et al.
Parkinsonism & Related Disorders|July 10, 2013
The effect of Tai Chi exercise on gait initiation and gait performance in persons with Parkinson's diseaseShinichi Amano, Joe R Nocera, Srikant Vallabhajosula, et al.
CNS Drugs|March 14, 2018
Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's DiseaseLawrence W Elmer, Jorge L Juncos, Carlos Singer, et al.
Neurourology and Urodynamics|June 13, 2019
Behavioral therapy for urinary symptoms in Parkinson's disease: A randomized clinical trialCamille P Vaughan, Kathryn L Burgio, Patricia S Goode, et al.
CNS Drugs|April 12, 2018
Author Correction to: Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's DiseaseLawrence W Elmer, Jorge L Juncos, Carlos Singer, et al.
Neurourology and Urodynamics|November 3, 2017
Increased odds of bladder and bowel symptoms in early Parkinson's diseaseMonica C Serra, Alexus Landry, Jorge L Juncos, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 27, 2004
Quetiapine improves psychotic symptoms and cognition in Parkinson's diseaseJorge L Juncos, Vicki J Roberts, Marian L Evatt, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Movement Disorders : Official Journal of the Movement Disorder Society|October 20, 2012
Olfactory dysfunction in fragile X tremor ataxia syndromeJorge L Juncos, Joash T Lazarus, Julia Rohr, et al.
Archives of Neurology|November 16, 2002
Beneficial effects of testosterone replacement for the nonmotor symptoms of Parkinson diseaseMichael S Okun, Benjamin L Walter, William M McDonald, et al.
The Lancet. Neurology|November 14, 2009
Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disordersValerie Voon, Pierre-Olivier Fernagut, Jeff Wickens, et al.
Neurogenetics|February 1, 2011
New clinical findings in the fragile X-associated tremor ataxia syndrome (FXTAS)Jorge L Juncos, Joash T Lazarus, Emily Graves-Allen, et al.
Parkinsonism & Related Disorders|July 10, 2013
The effect of Tai Chi exercise on gait initiation and gait performance in persons with Parkinson's diseaseShinichi Amano, Joe R Nocera, Srikant Vallabhajosula, et al.
CNS Drugs|March 14, 2018
Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's DiseaseLawrence W Elmer, Jorge L Juncos, Carlos Singer, et al.
Neurourology and Urodynamics|June 13, 2019
Behavioral therapy for urinary symptoms in Parkinson's disease: A randomized clinical trialCamille P Vaughan, Kathryn L Burgio, Patricia S Goode, et al.
CNS Drugs|April 12, 2018
Author Correction to: Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's DiseaseLawrence W Elmer, Jorge L Juncos, Carlos Singer, et al.
Neurourology and Urodynamics|November 3, 2017
Increased odds of bladder and bowel symptoms in early Parkinson's diseaseMonica C Serra, Alexus Landry, Jorge L Juncos, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 27, 2004
Quetiapine improves psychotic symptoms and cognition in Parkinson's diseaseJorge L Juncos, Vicki J Roberts, Marian L Evatt, et al.
Pageof 4